Head of the FDA, Scott Gottlieb has suggested some ways in which pharma giants could rethink their business models, to help unproductive drugmakers.
Genomics has the potential to significantly improve the efficacy of drugs and develop targeted therapies.
The FDA has approved Seattle Genetics’ Hodgkin’s lymphoma treatment, which is the first to be approved to treat the disease in over 40 years.
Experts have revealed that cut-price copies of an expensive Roche biotech drug for blood cancer have taken 80% of the British market since launching last year, saving the healthcare system £80 million a year.
Going against industry trend of backing out of the neuroscience field, is Celgene, who is about to put down a potential $2.2 million to gain options on three Prothena drug candidates.
A team of researchers is finding different ways of using existing drugs to treat the rarest of diseases, saving huge research costs.
Chinese pharmaceutical companies are proving their place in the US generic drugs market, with a rising number of approvals for copycat medicines almost doubling in the past year.
FDA Commissioner, Scott Gottlieb has critiqued health insurers, as he homes in on the increasingly popular target of rebates in the drug pricing debate.
Using an epigenetic mechanism, romidepsin restored gene expression and alleviated social deficits in animal models of autism.
The World Health Organisation (WHO) has put scientists and health workers around the globe on alert for a new and potentially deadly pathogen – Disease X.
In a new study with mice, researchers have discovered a new way to treat urinary tract infections (UTIs) without using antibiotics.
With the help of a new radioactive tracer, doctors can predict with more than 80 percent accuracy how well a widely-used lung cancer drug will combat tumours.